These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37740841)

  • 21. Impact of biological therapy in reducing the risk of arthritis development in inflammatory bowel diseases.
    Fatica M; Monosi B; Conigliaro P; D'Antonio A; Essofi S; Cuccagna E; Bergamini A; Biancone L; Monteleone G; Triggianese P; Calabrese E; Chimenti MS
    RMD Open; 2024 Jan; 10(1):. PubMed ID: 38296800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 2018 APLAR axial spondyloarthritis treatment recommendations.
    Tam LS; Wei JC; Aggarwal A; Baek HJ; Cheung PP; Chiowchanwisawakit P; Dans L; Gu J; Hagino N; Kishimoto M; Reyes HM; Soroosh S; Stebbings S; Whittle S; Yeap SS; Lau CS
    Int J Rheum Dis; 2019 Mar; 22(3):340-356. PubMed ID: 30816645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis.
    Nissen MJ; Ciurea A; Bernhard J; Tamborrini G; Mueller R; Weiss B; Toniolo M; Exer P; Gabay C; Finckh A;
    Arthritis Rheumatol; 2016 Sep; 68(9):2141-50. PubMed ID: 27015429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
    BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in the treatment of uveitis in patients with spondyloarthritis - is it the time for biologic therapy?
    Mitulescu TC; Trandafir M; Dimăncescu MG; Ciuluvică RC; Popescu V; Predețeanu D; Istrate S; Voinea LM
    Rom J Ophthalmol; 2018; 62(2):114-122. PubMed ID: 30206554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.
    van der Heijde D; Ramiro S; Landewé R; Baraliakos X; Van den Bosch F; Sepriano A; Regel A; Ciurea A; Dagfinrud H; Dougados M; van Gaalen F; Géher P; van der Horst-Bruinsma I; Inman RD; Jongkees M; Kiltz U; Kvien TK; Machado PM; Marzo-Ortega H; Molto A; Navarro-Compàn V; Ozgocmen S; Pimentel-Santos FM; Reveille J; Rudwaleit M; Sieper J; Sampaio-Barros P; Wiek D; Braun J
    Ann Rheum Dis; 2017 Jun; 76(6):978-991. PubMed ID: 28087505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.
    Ramiro S; Nikiphorou E; Sepriano A; Ortolan A; Webers C; Baraliakos X; Landewé RBM; Van den Bosch FE; Boteva B; Bremander A; Carron P; Ciurea A; van Gaalen FA; Géher P; Gensler L; Hermann J; de Hooge M; Husakova M; Kiltz U; López-Medina C; Machado PM; Marzo-Ortega H; Molto A; Navarro-Compán V; Nissen MJ; Pimentel-Santos FM; Poddubnyy D; Proft F; Rudwaleit M; Telkman M; Zhao SS; Ziade N; van der Heijde D
    Ann Rheum Dis; 2023 Jan; 82(1):19-34. PubMed ID: 36270658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics.
    Osiri M; Wongpiyabovorn J; Sattayasomboon Y; Thammacharoenrach N
    Clin Rheumatol; 2016 Jul; 35(7):1673-81. PubMed ID: 27188857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can we reduce the dosage of biologics in spondyloarthritis?
    Olivieri I; D'Angelo S; Padula A; Leccese P; Nigro A; Palazzi C
    Autoimmun Rev; 2013 May; 12(7):691-3. PubMed ID: 22940233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of relapse rates and risk factors of tapering or stopping pharmacologic therapies in axial spondyloarthritis patients with sustained remission.
    Chen X; Zhang T; Wang W; Xue J
    Clin Rheumatol; 2018 Jun; 37(6):1625-1632. PubMed ID: 29667099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical characteristics of importance to outcome in patients with axial spondyloarthritis: protocol for a prospective descriptive and exploratory cohort study.
    Andreasen RA; Kristensen LE; Ellingsen T; Christensen R; Baraliakos X; Wied J; Aalykke C; Ulstrup T; Schiøttz-Christensen B; Horn HC; Emamifar A; Duerlund B; Fischer L; Hansen IMJ
    BMJ Open; 2017 Jul; 7(7):e015536. PubMed ID: 28698330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment challenges in axial spondylarthritis and future directions.
    Sieper J
    Curr Rheumatol Rep; 2013 Sep; 15(9):356. PubMed ID: 23888365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
    RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Add-On Effects of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs in Ankylosing Spondylitis: Data from a Real-World Registered Study in China.
    Man S; Ji X; Wang Y; Ma Y; Hu Z; Zhu J; Zhang J; Huang F
    Med Sci Monit; 2020 Jan; 26():e921055. PubMed ID: 31959738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of sulfasalazine in axial spondyloarthritis on COVID-19 outcomes: real-life data from a single center.
    Armağan B; Atalar E; Güven SC; Özdemir B; Konak HE; Akyüz Dağlı P; Erden A; Gök K; Maraş Y; Doğan İ; Küçükşahin O; Erten Ş; Omma A
    Immunopharmacol Immunotoxicol; 2023 Dec; 45(4):395-401. PubMed ID: 36537308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis.
    G S Saad C; S R Silva M; Sampaio-Barros PD; C B Moraes J; G Schainberg C; Gonçalves CR; Shimabuco AY; Aikawa NE; F N Yuki E; G Pasoto S; V K Kupa L; K Aoyama R; S R Araujo C; Silva CA; Medeiros-Ribeiro AC; Bonfa E
    Joint Bone Spine; 2023 Jan; 90(1):105464. PubMed ID: 36150668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Appropriate management of axial spondyloarthritis.
    LaSalle SP; Deodhar AA
    Curr Rheumatol Rep; 2007 Oct; 9(5):375-82. PubMed ID: 17915093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-TNFs in axial spondyloarthritis.
    Kocijan R; Muschitz C; Rech J
    Wien Med Wochenschr; 2015 Jan; 165(1-2):10-3. PubMed ID: 25572548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Biggioggero M; Benucci M; Li Gobbi F; Grossi V; Infantino M; Meacci F; Manfredi M; Guiducci S; Bellando-Randone S; Matucci-Cerinic M; Foti R; Di Gangi M; Mosca M; Tani C; Palmieri F; Goletti D;
    Semin Arthritis Rheum; 2016 Apr; 45(5):519-32. PubMed ID: 26607440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The perioperative use of synthetic and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Fleury G; Mania S; Hannouche D; Gabay C
    Swiss Med Wkly; 2017; 147():w14563. PubMed ID: 29231235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.